Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

NCT02244333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4575

Last updated 2014-09-19

No results posted yet for this study

Summary

Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment

Conditions

  • Prostatic Hyperplasia

Interventions

DRUG

ALNA®

Sponsors & Collaborators

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2004-07-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02244333 on ClinicalTrials.gov